| 引用本文: | 李志豪,邓组跃,黄逸伦,陈书恺,蒋霞,任艳云.巴戟天多糖通过P2X7R/NLRP3通路抑制大鼠骨质疏松[J].中国现代应用药学,2026,43(3):48-57. |
| Lizhihao,dengzuyue,huangyilun,chenshukai,jiagnxia,renyanyun.Morinda officinalis polysaccharides inhibit osteoporosis in rats via the P2X7R/NLRP3 pathway[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(3):48-57. |
|
| 摘要: |
| 目的 研究巴戟天多糖抑制骨质疏松的作用机制，尤其是其对P2X7R/NLRP3炎症小体通路的调节。方法 将100只雌性SD大鼠随机分成10组，包括：假手术组、骨质疏松模型组、不同巴戟天多糖剂量给药组（低剂量组50mg/kg，中剂量组100mg/kg，高剂量组200mg/kg，均为口服）、己烯雌酚阳性组（0.1mg/kg，口服）、考马斯亮蓝G抑制剂组（75mg/kg，腹腔注射给药）、巴戟天多糖中剂量+考马斯亮蓝G联合给药组（巴戟天多糖100mg/kg +考马斯亮蓝G 75mg/kg联合给药），氟甲基酮抑制剂组（0.15mg/kg，静脉给药）、巴戟天多糖中剂量+氟甲基酮联合给药组（巴戟天多糖 100mg/kg +氟甲基酮 0.15mg/kg联合给药）。每组各10只。通过双侧卵巢摘除法制备骨质疏松模型。各治疗组按照相应剂量给予药物，假手术对照组和模型组灌胃等量生理盐水。经过6周的连续给药后，处死各组大鼠。采用Micro-CT测定骨微结构参数（BMD，Tb.N，Tb.Sp，Tb.Th，和BV/TV），利用ELISA试剂盒检测血清中骨代谢相关因子（BMP-2、BALP、OC、CTX-I）及炎症因子（TNF-α、IL-6、IL-1β、IL-18）的水平；通过Western blot法检测P2X7R、NLRP3、Caspase-1、GSDMD-N、OPG、RANKL等蛋白的表达情况。最后，采用HE染色观察各组大鼠骨组织的病理变化。结果 给予巴戟天多糖治疗的大鼠骨质疏松愈合明显，骨微结构参数BMD，Tb.N，Tb.Th和BV/TV显著增加，Tb.Sp降低；病理结果显示骨小梁数量增加，平均骨小梁面积增加，骨小梁间隙显著降低，炎性细胞浸润减少；同时，血清中BMP-2、BALP、OC水平上升，CTX-I、TNF-α、IL-6、IL-1β、IL-18水平下降。此外，巴戟天多糖也上调了骨组织中OPG蛋白的表达，下调了P2X7R、RANKL、NLRP3、Caspase-1和GSDMD-N蛋白的表达。考马斯亮蓝G和氟甲基酮均可增加巴戟天多糖促进骨质疏松的愈合。结论 巴戟天多糖可通过抑制P2X7R-NLRP3炎症小体通路调节骨质疏松状态下的炎症因子水平，从而发挥抗骨质疏松作用。 |
| 关键词: 巴戟天多糖 骨质疏松 P2X7R NLRP3 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Morinda officinalis polysaccharides inhibit osteoporosis in rats via the P2X7R/NLRP3 pathway |
|
Lizhihao1, dengzuyue2, huangyilun3, chenshukai3, jiagnxia4, renyanyun5,6,7
|
|
1.Zhejiang University of Technology;2.Zhejiang University of Technology， Zhejiang Institute for Food and Drug Control;3.Wenzhou Medical University;4.Zhejiang Institute for Food and Drug Control;5.The 903rd Hospital of the Joint Logistics Support Force of the Chinese People'6.'7.s Liberation Army
|
| Abstract: |
| Objective To investigate the mechanism of morinda officinalis polysaccharide inhibiting osteoporosis，especially its regulation of P2X7R/NLRP3 inflammasome pathway. Methods 100 female SD rats were randomly divided into 10 groups, including: Sham group, osteoporosis model group, different doses of morinda officinalis polysaccharide treatment group (50mg/kg in low dose group, 100mg/kg in medium dose group and 200mg/kg in high dose group, all orally), diethylstilbestrol positive group (0.1 mg/kg, oral), Coomassie Brilliant Blue G inhibitor group (75mg/kg, intraperitoneal injection), morinda officinalis polysaccharide +Coomassie Brilliant Blue G Co-administration group (morinda officinalis polysaccharide 100mg/kg +Coomassie Brilliant Blue G 75mg/kg administered in combination), fluoromethyl ketone inhibitor group (0.15 mg/kg, intravenous), morinda officinalis polysaccharide + fluoromethyl ketone Co-administration group (MOP 100mg/kg +Z-YVAD 0.15 mg/kg administered in combination). Each group had 10 rats. Osteoporo |
| Key words: morinda officinalis polysaccharide osteoporosis P2X7R NLRP3 |
